Heterogeneity was seen across UPF subtypes, with lower incident type 2 diabetes for breads, cereals, plant-based alternatives
FRIDAY, Sept. 27, 2024 (HealthDay News) — A higher intake of ultraprocessed food (UPF) is associated with an increased incidence of type 2 diabetes mellitus, according to a study published online Sept. 16 in The Lancet Regional Health.
Samuel J. Dicken, from University College London, and colleagues conducted a prospective cohort analysis of the European Prospective Investigation into Cancer and Nutrition cohort to examine the association between degree of food processing and incident type 2 diabetes. Dietary intake was assessed at baseline and classified as unprocessed/minimally processed food (MPF), processed culinary ingredients (PCI), processed food (PF), and UPF.
The researchers identified 14,236 type 2 diabetes mellitus cases during an average 10.9 years of follow-up of 311,892 individuals. Incident type 2 diabetes was 17 percent higher in association with each 10 percent increment of total daily food intake from UPF. The incidence of type 2 diabetes mellitus was lower in association with each 10 percent increment in MPF + PCI (hazard ratio, 0.94) or PF intake (hazard ratio, 0.92). Lower incident type 2 diabetes mellitus was seen in association with replacing UPF with MPF + PCI or PF. Heterogeneity was seen across subgroups of UPF, with lower incident type 2 diabetes mellitus in association with breads, biscuits and breakfast cereals, sweets and desserts, and plant-based alternatives.
“Higher UPF intake was associated with higher incident type 2 diabetes mellitus, whereas higher intakes of foods with less processing were associated with lower incident type 2 diabetes mellitus,” the authors write.
One author disclosed ties to Amazon; a second author disclosed ties to the biopharmaceutical industry.
Study IDs Risk Factors for Ketoacidosis in Adults With T2D Receiving SGLT2 Inhibitors
Genetics, Diabetes Tied to MASLD-Associated Cirrhosis Before Age 50
Long-Term Medication Adherence Tied to Lower Cardiovascular Event Rate in Type 2 Diabetes
Add-On Tirzepatide May Reduce MACE Risk in People With T2D, ASCVD
Report Highlights Substance Use in Young Adults in U.S. in 2025
Considerable Gaps Identified in LDL Cholesterol Control
Link Between Liver Fibrosis in MASLD, ASCVD Varies by Glycemic Status
Semaglutide Not Linked to Higher Neovascular Age-Related Macular Degeneration Risk